Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England

The NHS Commissioning Board (operating under the name of NHS England)

This public procurement record has 1 release in its history.

Award

28 Apr 2021 at 16:29

Award Notice
Summary of the contracting process

The NHS Commissioning Board (operating as NHS England) has completed a public procurement process for the National Framework Agreement concerning the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies in the North of England. This procurement is classified under the pharmaceutical products category and encompasses various lots covering specific medications. The framework agreement commenced on 1 April 2021 and is set for a duration of 12 months, with potential extensions, allowing for a total of up to 48 months. The procurement was conducted using an open procedure.

This framework presents significant opportunities for businesses, particularly those involved in the pharmaceutical sector, including manufacturers and suppliers of cytotoxic medicines and monoclonal antibodies. Companies with expertise in aseptic preparation and those that can meet the rigorous standards expected in healthcare delivery would be well-placed to compete. Furthermore, the process allows for involvement from both large enterprises and small and medium-sized enterprises (SMEs), providing a broad range of businesses the chance to contribute to the UK's healthcare supply chain.

How relevant is this notice?

Notice Information

Notice Title

National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England

Notice Description

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Lot Information

Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Atezolizumab - Lot 1

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Avastin) - Lot 2

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Zirabev) - Lot 3

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Aybintio) - Lot 4

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bleomycin - Lot 5

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Cyclophosphamide Bags - Lot 11

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Obinutuzumab - Lot 33

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Pemetrexed - Lot 38

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fludarabine Bags - Lot 17

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Ganciclovir - Lot 27

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Methotrexate - Lot 31

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil Bags - Lot 19

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Bortezomib - Lot 6

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Pertuzumab - Lot 39

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Carboplatin - Lot 7

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Panitumumab - Lot 36

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Vinorelbine - Lot 50

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Irinotecan - Lot 30

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fludarabine Syringes - Lot 16

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Trastuzumab (Trasimera) - Lot 47

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Pembrolizumab - Lot 37

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cetuximab - Lot 8

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Docetaxel - Lot 13

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil Syringes - Lot 18

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Doxorubicin - Lot 14

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Cytarabine - Lot 12

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Nivolumab - Lot 32

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cyclophosphamide Syringes - Lot 10

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Trastuzumab (Herzuma) - Lot 44

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Oxaliplatin - Lot 34

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Vinblastine - Lot 48

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cisplatin - Lot 9

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Gemcitabine - Lot 28

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Vincristine - Lot 49

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Herceptin) - Lot 43

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Ontruzant) - Lot 46

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Epirubicin - Lot 15

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Rituximab (Truxima) - Lot 42

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Rituximab (Mabthera) - Lot 40

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Rituximab (Rixathon) - Lot 41

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Paclitaxel - Lot 35

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Kanjinti) - Lot 45

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02ab4a
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/009177-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
28 Apr 20215 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
18 Mar 20215 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England
Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
Not specified
Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
4
Supplier Names

Baxter Healthcare Ltd

ITH Pharma

Qualasept Ltd t/a Bath ASU

Quantum Aseptic Services

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...